Sarclisa SC PDUFA Delay & Multiple Myeloma OBI Strategy
Analyze the FDA's three-month PDUFA delay for subcutaneous Sarclisa. Examine its on-body injector technology, clinical data, and anti-CD38 competitors.
Back to Articles
Articles tagged with “on-body-injector”